Apigenin is a plant flavonoid in parsley, celery, and chamomile, valued for its calming effect. The most credible human benefits are better sleep and reduced anxiety; broader claims around inflammation, brain, metabolism, and aging rest on cell and animal data. Poor absorption is the central limitation. Low-cost, low-risk, with modest evidence. (Full Review)

Protocol

Standard Dose

50 mg

Taken 30–60 minutes before bed, often stacked with magnesium and L-theanine

Timing

Evening only

Daytime dosing risks drowsiness; single evening dose given the long half-life

Starting Dose

25–50 mg

Begin at the lower end to assess sedation sensitivity; older adults start at 25 mg

Time to effect

Sleep / Calm

30–60 minutes

Sedative/calming effects are felt within 30–60 minutes of an evening dose

Anxiety Reduction

~8 weeks

In chamomile GAD trials, reductions on anxiety scales emerged over 8 weeks

Metabolic / Longevity

Months

Any putative metabolic or longevity effects would accrue over months and are not subjectively perceptible

Benefits

Medium: Sleep quality; anxiety reduction

Low: Anti-inflammatory effects; cognitive and neuroprotective support; cardiometabolic and metabolic syndrome support

Speculative: NAD⁺ preservation and longevity; anticancer effects; senolytic/senomorphic aging effects

Contraindications

Pregnancy or breastfeeding

Asteraceae-family allergy (ragweed, daisy)

Hormone-sensitive cancers

Surgery within ~2 weeks

Key Interactions

Sedatives and CNS depressants (benzodiazepines, Z-drugs, alcohol)

Other sleep/calming supplements (magnesium, L-theanine, melatonin, valerian)

Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel)

Drugs metabolized by CYP450/UGT (statins, calcium-channel blockers, immunosuppressants)

Hormone-modulating therapies (tamoxifen, aromatase inhibitors)

Risk & Side Effects

Low: Sedation and daytime drowsiness; allergic reactions

Speculative: Hormonal and phytoestrogenic effects; drug-metabolism interference; bleeding risk and pregnancy concerns

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation, apigenin's proposed anti-inflammatory target
Fasting glucose	70–90 mg/dL	Context for metabolic-syndrome rationale
Fasting insulin	2–5 µIU/mL	Sensitive early marker of metabolic health
ALT	< 25 U/L (men), < 20 U/L (women)	Liver status, relevant to apigenin's enzyme-inhibition potential
Lipid panel (LDL-C, HDL-C, triglycerides)	Triglycerides < 80 mg/dL	Context for cardiometabolic rationale

Cadence: Baseline, then every 6–12 months

Qualitative Assessment

Sleep quality (time to fall asleep, night-time awakenings, morning refreshment)
Subjective anxiety and evening calm
Daytime alertness (to catch unwanted next-day grogginess)
Energy levels and cognitive clarity over weeks to months

Apigenin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment